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Introduction
von Willebrand disease (VWD) is the most commonly diagnosed autosomally inherited bleeding disorder. It affects approximately one in 10,000 individuals sufficiently to be referred to a tertiary care centre. 1 von Willebrand factor (VWF) is a very large multimeric glycoprotein 2 that performs two essential haemostatic functions; it provides a means to bind platelets at sites of vascular damage and at high shear stress supports platelet aggregation. It also carries and protects coagulation factor VIII (FVIII) in the circulation, delivering it to sites of vascular injury.
Initial analysis for possible VWD examines bleeding symptoms in the patient and their family and this typically includes epistaxis, easy bruising and other haemorrhagic symptoms. A bleeding score (BS) system has been defined and can help predict outcomes and replacement therapy. 3 Laboratory testing of quantity and activity parameters for VWF then determine whether they deviate from the normal range. VWD is divided into three main categories; type 1 VWD (VWD1) is a partial quantitative deficiency, and VWD3 an almost complete quantitative deficiency of VWF whilst VWD2
is categorised into 4 types; 2A, 2B, 2M and 2N dependent on VWF function perturbed by mutation.
Recently, guidelines on the diagnosis and management of VWD have recommended that cut-off values are used in the diagnostic pathway. These suggest that patients having VWF activity levels -35 IU L VWF bleeding, rather than being given a VWD diagnosis. 4, 5 For many patients diagnosed with VWD, laboratory phenotypic assays readily suggest VWD type in the individual, enabling the clinical team to select the most relevant management for that disease type. However, where this is not the case, genetic analysis can help understand the pa disorder through identification of the causative mutation(s). For many years, PCR and Sanger sequencing were utilised to identify mutations in the VWF gene (VWF), but more recently, next generation sequencing (NGS) has been introduced to diagnostic and research institutions. This technology enables simultaneous parallel sequencing of many genes. Large deletions and duplications of an exon or more can be sought using multiplex ligation-dependent probe amplification (MLPA) or microarray specific for VWF, or through analysis of NGS data using an algorithm to seek missing or duplicated regions.
This article summarises the mutation classes and their inheritance patterns associated with the different VWD types and how this information can be useful in provision of the most relevant patient management. Mutations are located throughout VWF from the promoter region 10 to exon 52, 11, 12 the majority are missense mutations (75%), while splice, deletion, nonsense, insertion, duplication and large in-frame deletions mutations comprise minor proportions. 13 Most patients have dominantly inherited disease resulting from a single mutation whilst a smaller proportion (~5-10%) have more than one mutation contributing to their symptoms, some with recessive inheritance. [14] [15] [16] Blood-group O is present in up to ~65% of VWD1.
Type 1 VWD
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The predominant mechanism responsible is intracellular retention of mutant VWF, resulting in reduced secretion into plasma. 17 Rapid VWF clearance from the circulation also contributes, 18 with The main use for genetic analysis in VWD1 is to help understand the cause of the more severe presentations and inheritance risk for family members.
Other genes that contribute to variation in VWF level
The 
D3 domain
The VWD2A/IIE phenotype was described many years ago, but mutations responsible were only described as a single VWD category in 2010. 28 Mutations result in intracellular retention, relative loss of HWMW and reduced ADAMTS13-mediated proteolysis. Missense mutations are located in ex22
and 25-28, many introducing/substituting cysteine residues; replacement of p.Cys1130 is the most common change. 29 These mutations, like p.Arg1205His result in rapid VWF clearance.
D2 domain
VWD2A/IIC propeptide mutations have a multimerisation defect resulting in reduced HMWM. Unlike most VWD2A, mutations are recessively inherited and are located in ex11-16 (AA 404-768). In addition to homozygous missense mutations, patients also have small in-frame deletions/insertions with some being compound heterozygous.
CK domain
VWD2A/IID mutations are located in the cysteine knot domain and affect ex51-52 (AA 2730-2801).
Mutations impair VWF dimerisation leading to odd numbered satellite bands on multimer analysis. 30 Mutation analysis can aid understanding of disease process in VWD2A either through analysis of exon 28 alone or preferably of the entire gene.
Type 2B VWD
VWD2B results from an unusual gain-of-function mutation type. 31 38 Inheritance is recessive; at least one of the two mutations affects VWF:FVIIIB. The second mutation can be a further copy of the same missense mutation, a different VWF:FVIIIB missense mutation or commonly a null allele (nonsense, splice-site, deletion/insertion). The most frequent mutation in the European populations is p.Arg854Gln, for which ~1% individuals are heterozygous.
Unless there is an obvious family history indicating inheritance pattern, it can be difficult to distinguish mild haemophilia A from 2N VWD. A phenotypic VWF:FVIIIB assay or genetic analysis to discriminate these two disorders can be used. Desmopressin response may be curtailed in 2N patients due to shortened FVIII half-life.
Type 3 VWD
In populations where consanguineous partnerships are common, the prevalence of VWD3 may be 
Clinical utility of VWF genetic testing
Molecular testing for VWD is justified in individuals in whom phenotypic assays suggest VWD, but genetic analysis may provide a more specific diagnosis to aid appropriate management. Examples are; to distinguish between VWD2N, mild hemophilia A in males, or symptomatic hemophilia carrier status in females; to discriminate between VWD2B and platelet-type pseudo VWD (PT-VWD), to phenotype and to provide prenatal diagnosis for families with VWD3. For VWD1, patients where rapid VWF clearance occurs following desmopressin administration or when inheritance pattern is unclear and mutation determination can explain disease risk in relatives, genetic analysis can be useful.
Conclusion
VWF mutations are located throughout the VWF gene, resulting in a wide range of mutation types that include quantitative and qualitative disorders. VWF protein is involved in several processes that can be damaged by mutation and the varying phenotypes in VWD illustrate the processes impaired.
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